These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2668648)

  • 21. Bone marrow stromal culture from patients with myelodysplastic syndromes and patients at different stages of acute nonlymphocytic leukaemia.
    Elstner E; Wächter M; Ihle R
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(1):167-74. PubMed ID: 2472321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes].
    Dvirnyk VN; Kokhno AV; Glasko EN; Gemdzhian ÉG; Diagileva OA; Platonova TL; Parovichnikova EN
    Ter Arkh; 2013; 85(7):65-71. PubMed ID: 24137949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The myelodysplastic syndromes.
    Verwilghen RL; Boogaerts MA
    Blood Rev; 1987 Mar; 1(1):34-43. PubMed ID: 3332085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.
    Frietsch JJ; Dornaus S; Neumann T; Scholl S; Schmidt V; Kunert C; Sayer HG; Hochhaus A; La Rosée P
    Eur J Haematol; 2014 Sep; 93(3):247-59. PubMed ID: 24635656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes.
    Hellström E; Robèrt KH; Soppi E; Ost A; Putkonen PO; Gahrton G
    Leuk Res; 1989; 13(12):1113-21. PubMed ID: 2615468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
    Cheson BD; Jasperse DM; Simon R; Friedman MA
    J Clin Oncol; 1986 Dec; 4(12):1857-64. PubMed ID: 3537219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes.
    Micheva I; Thanopoulou E; Michalopoulou S; Karakantza M; Kouraklis-Symeonidis A; Mouzaki A; Zoumbos N
    Clin Immunol; 2004 Dec; 113(3):310-7. PubMed ID: 15507396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of rHuEpo in low-risk myelodysplastic syndrome patients.
    Rigolin GM; Castoldi G
    Leuk Lymphoma; 2005 Jun; 46(6):823-31. PubMed ID: 16019526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premature chromosome condensation in the study of minimal residual disease.
    Hittelman WN; Tigaud JD; Estey E; Vadhan-Raj S
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():9-13. PubMed ID: 2202475
    [No Abstract]   [Full Text] [Related]  

  • 31. [Mechanism and problem of amifostine in treating myelodysplastic syndromes].
    Dang YH; Li W; Yang B; Zhu HL; Huang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1597-601. PubMed ID: 20030955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelodysplastic syndromes.
    Nguyen PL; Xu Y; Jatoi A
    Am J Clin Pathol; 2003 Dec; 120 Suppl():S25-37. PubMed ID: 15298141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of the myelodysplastic syndromes.
    Tricot G; Mecucci C; Van den Berghe H
    Br J Haematol; 1986 Aug; 63(4):609-14. PubMed ID: 3524660
    [No Abstract]   [Full Text] [Related]  

  • 36. Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome.
    Daw S; Chatterjee R; Law A; Law S
    Chem Biol Interact; 2016 Dec; 260():176-185. PubMed ID: 27725143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic nature of the myelodysplastic syndromes.
    Greenberg PL
    Acta Haematol; 1987; 78 Suppl 1():94-9. PubMed ID: 2829490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differentiation therapy for myelodysplastic syndrome].
    Hino K; Nakamaki T
    Rinsho Ketsueki; 1993 Mar; 34(3):283-8. PubMed ID: 7683064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization.
    Rigolin GM; Cuneo A; Roberti MG; Bardi A; Castoldi G
    Haematologica; 1997; 82(1):25-30. PubMed ID: 9107078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia.
    Yoshida Y; Stephenson J; Mufti GJ
    Int J Hematol; 1993 Apr; 57(2):87-97. PubMed ID: 8494998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.